1. Academic Validation
  2. Semisynthetic Derivatives of the Verticillin Class of Natural Products through Acylation of the C11 Hydroxy Group

Semisynthetic Derivatives of the Verticillin Class of Natural Products through Acylation of the C11 Hydroxy Group

  • ACS Med Chem Lett. 2021 Mar 19;12(4):625-630. doi: 10.1021/acsmedchemlett.1c00024.
Chiraz Soumia M Amrine 1 2 Andrew C Huntsman 3 Michael G Doyle 1 Joanna E Burdette 4 Cedric J Pearce 5 James R Fuchs 3 Nicholas H Oberlies 1
Affiliations

Affiliations

  • 1 Department of Chemistry and Biochemistry, University of North Carolina at Greensboro, Greensboro, North Carolina 27402, United States.
  • 2 Department of Physical Sciences, Arkansas Tech University, Russellville, Arkansas 72801, United States.
  • 3 Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Ohio State University, Columbus, Ohio 43210, United States.
  • 4 Department of Pharmaceutical Sciences, Center for Biomolecular Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60607, United States.
  • 5 Mycosynthetix, Inc., 505 Meadowlands Drive, Suite 103, Hillsborough, North Carolina 27278, United States.
Abstract

The verticillins, a class of epipolythiodioxopiperazine Alkaloids (ETPs) first described 50 years ago with the discovery of verticillin A (1), have gained attention due to their potent activity against Cancer cells, noted both in vitro and in vivo. In this study, the complex scaffold afforded through optimized fermentation was used as a feedstock for semisynthetic efforts designed to explore the reactivity of the C11 and C11' hydroxy substituents. Functionality introduced at these positions would be expected to impact not only the potency but also the pharmacokinetic properties of the resulting compound. With this in mind, verticillin H (2) was used as a starting material to generate nine semisynthetic analogues (4-12) containing a variety of ester, carbonate, carbamate, and sulfonate moieties. Likewise, verticillin A succinate (13) was synthesized from 1 to demonstrate the successful application of this strategy to Other ETPs. The synthesized compounds and their corresponding starting Materials (i.e., 1 and 2) were screened for activity against a panel of melanoma, breast, and ovarian Cancer cell lines: MDA-MB-435, MDA-MB-231, and OVCAR3. All analogues retained IC50 values in the nanomolar range, comparable to, and in some cases more potent than, the parent compounds.

Figures